Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

BACKGROUND: This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic dru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L., DeLozier, Amy M., Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A. F.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604362/
https://ncbi.nlm.nih.gov/pubmed/28923098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1410-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados